Arctic Bioscience - Notice of Annual General Meeting on 26 May 2025

12 May 2025 09:00 CEST

Arctic Bioscience AS' Annual General Meeting will be held Monday 26 May 2025 at
11:00 (CET), as a digital meeting.

Shareholders are encouraged to cast their votes in advance of the General
Meeting or grant the Chair of the Board a proxy, with or without voting
instructions.

The deadline for registration of attendance, advance votes, proxy or
instructions is 22 May 2025 at 16:00 (CET). For attendance at the live event,
please follow the instructions in the notice.

For further information, see the attached Notice of the Annual General Meeting,
which can also be accessed from the company's website (https://arctic
-bioscience.com/investors/general-meetings/).

Board of Directors proposal:

Proposed board members for the next period are:

· Harald Nordal (chairperson) (reelection)
· Jan Endre Vartdal (reelection)
· Tore A. F. Tønseth (reelection)
· Marita Holstad (reelection)
· Olav Sindre Kriken (new)

Proposed new board member Olav Sindre Kriken is a Norwegian citizen from Ørsta
based in Palo Alto, California. Mr. Kriken is an experienced Founder and
Businessman with a solid record within business innovation and growth. He is
skilled in Product-Led Growth, Business Modelling, Marketing Management and
Digital Strategy. The nomination of Mr. Kriken to the company board is aligned
with the company growth within product sales through established and new
distributions channels with strategic utilization of the opportunities with AI
and SoMe.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

646007_20250512_Arctic_Bioscience_AS_Notice_AGM_2025.pdf